KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CareDx (CDNA) Total Current Liabilities (2016 - 2025)

CareDx's Total Current Liabilities history spans 13 years, with the latest figure at $93.2 million for Q2 2025.

  • For Q2 2025, Total Current Liabilities changed N/A year-over-year to $93.2 million; the TTM value through Jun 2025 reached $93.2 million, changed N/A, while the annual FY2023 figure was $78.1 million, 2.76% up from the prior year.
  • Total Current Liabilities for Q2 2025 was $93.2 million at CareDx, up from $85.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $93.2 million in Q2 2025 and bottomed at $45.7 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $76.0 million (2022), against an average of $73.5 million.
  • The largest annual shift saw Total Current Liabilities soared 61.45% in 2021 before it decreased 1.72% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $77.3 million in 2021, then fell by 1.72% to $76.0 million in 2022, then rose by 2.76% to $78.1 million in 2023, then increased by 4.31% to $81.4 million in 2024, then increased by 14.42% to $93.2 million in 2025.
  • Per Business Quant, the three most recent readings for CDNA's Total Current Liabilities are $93.2 million (Q2 2025), $85.3 million (Q1 2025), and $81.4 million (Q3 2024).